SCHEMBL8009074

SCHEMBL8009074

CNc1cnc(C)s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28783139 0.98 — —
SCHEMBL19047000 0.78 — —
SCHEMBL22797034 0.78 — —
Hydrochloric Acid SCHEMBL27944044 0.76 — —
SCHEMBL27677447 0.75 — —
SCHEMBL25475122 0.75 HCAR2 (0.42) —
SCHEMBL25571558 0.75 LRRK2 (0.37) —
SCHEMBL26077561 0.75 — —
SCHEMBL27879761 0.73 — —
SCHEMBL18236163 0.73 HCAR2 (0.44) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117964547-A Urea compound and application thereof as Sigma2 and 5HT2A dual-target inhibitor 瀚远医药有限公司 2024-05-03 — — CN disclosed
CN-111936496-B Heterocyclic compounds useful as medicaments 马萨里克大学 2023-12-29 — — CN disclosed
US-20230295159-A1 ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) 2023-09-21 — — US disclosed
US-20230271938-A1 BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES CAPELLA THERAPEUTICS, INC. 2023-08-31 — — US disclosed
CN-116583286-A Tetrahydrothienopyrimidine sulfonamide compounds 某久拉斯株式会社 2023-08-11 — — CN disclosed
CN-115806550-A Bicyclic BET bromodomain inhibitors and uses thereof 康威基内有限公司 2023-03-17 — — CN disclosed
WO-2023014943-A1 METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS 4E THERAPEUTICS, INC. (US) 2023-02-09 — — WO disclosed
WO-2023278686-A1 SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE 4E THERAPEUTICS, INC. (US) 2023-01-05 — — WO disclosed
CN-109641886-B Bicyclic BET bromodomain inhibitors and uses thereof 康威基内有限公司 2022-11-18 — — CN disclosed
WO-2022140428-A2 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2022-06-30 — — WO disclosed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN disclosed
CN-111936496-A Use of 4- (1H-imidazol-5-yl) -1H-pyrrolo [2,3-B ] pyridine for the treatment of leukemias, lymphomas and solid tumors 马萨里克大学 2020-11-13 — — CN disclosed
CN-102007123-B Heterocyclic inhibitors of stearoyl-CoA desaturase NOVARTIS AG 2014-04-30 — — CN disclosed
CN-101535303-B Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level NOVARTIS AG 2012-07-18 — — CN disclosed
CN-102007123-A Heterocyclic inhibitors of stearoyl-CoA desaturase NOVARTIS AG 2011-04-06 — — CN disclosed
WO-2009114870-A2 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2009-09-17 — — WO disclosed
WO-2009114874-A2 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2009-09-17 — — WO disclosed
CN-101535303-A Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level NOVARTIS AG (CH) 2009-09-16 — — CN disclosed
WO-2008104077-A1 SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) METHYLGENE INC. (CA) 2008-09-04 — — WO disclosed
EP-0034481-A1 2-Methyl-5-thiazole-methylamine and carboxamide derivatives Grigg, Ronald Ernest (GB) 1981-08-26 — — EP disclosed
Send feedback